[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

TR200002759T2 - Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı. - Google Patents

Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.

Info

Publication number
TR200002759T2
TR200002759T2 TR2000/02759T TR200002759T TR200002759T2 TR 200002759 T2 TR200002759 T2 TR 200002759T2 TR 2000/02759 T TR2000/02759 T TR 2000/02759T TR 200002759 T TR200002759 T TR 200002759T TR 200002759 T2 TR200002759 T2 TR 200002759T2
Authority
TR
Turkey
Prior art keywords
cabergoline
syndrome
treatment
leg numbness
numbness
Prior art date
Application number
TR2000/02759T
Other languages
English (en)
Inventor
Schueler Peter
Original Assignee
Pharmacia & Upjohn Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia & Upjohn Company filed Critical Pharmacia & Upjohn Company
Publication of TR200002759T2 publication Critical patent/TR200002759T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Bu bulus bacak uyusmasi sendromunun tedavisinde kabergolin ve farmasötik olarak kabul edilebilir tuzlarinin kullanimina iliskindir.
TR2000/02759T 1998-03-27 1999-03-24 Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı. TR200002759T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7963998P 1998-03-27 1998-03-27

Publications (1)

Publication Number Publication Date
TR200002759T2 true TR200002759T2 (tr) 2001-02-21

Family

ID=22151836

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2000/02759T TR200002759T2 (tr) 1998-03-27 1999-03-24 Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.

Country Status (23)

Country Link
US (1) US6114326A (tr)
EP (1) EP1066038B1 (tr)
JP (1) JP2002507562A (tr)
KR (1) KR100597517B1 (tr)
CN (1) CN1303286A (tr)
AT (1) ATE313326T1 (tr)
AU (1) AU747751B2 (tr)
BR (1) BR9908953A (tr)
CA (1) CA2320204A1 (tr)
CZ (1) CZ297284B6 (tr)
DE (1) DE69929041T2 (tr)
DK (1) DK1066038T3 (tr)
EA (1) EA002554B1 (tr)
ES (1) ES2255255T3 (tr)
HU (1) HUP0101954A3 (tr)
IL (1) IL138522A0 (tr)
NO (1) NO20004799L (tr)
NZ (1) NZ507176A (tr)
PL (1) PL343593A1 (tr)
SK (1) SK13312000A3 (tr)
TR (1) TR200002759T2 (tr)
WO (1) WO1999048484A2 (tr)
ZA (1) ZA200004452B (tr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
RS50070B (sr) 1997-12-22 2009-01-22 Euro-Celtique S.A., Oralni dozni oblik sa kombinacijom opijatnog agonista i antagonista
US6477408B1 (en) * 2000-03-07 2002-11-05 Northwestern University Analysis of muscular activity in neonatal animals to screen for mutations and/or drugs that alter sleep and wake states
GB0007309D0 (en) * 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Crystalline form V|| of cabergoline
GB0007308D0 (en) 2000-03-24 2000-05-17 Pharmacia & Upjohn Spa Process for preparing crystalline form | of cabergoline
US6426713B1 (en) * 2000-07-05 2002-07-30 Cirrus Logic, Inc. Independent control of calibration registers in a multi channel A-D converter
DE10066158B4 (de) * 2000-08-24 2007-08-09 Neurobiotec Gmbh Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms
DE10053397A1 (de) * 2000-10-20 2002-05-02 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
AR031152A1 (es) 2000-10-31 2003-09-10 Upjohn Co Tratamientos nuevos para el sindrome de piernas inquietas
DE10064453A1 (de) * 2000-12-16 2002-07-04 Schering Ag Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
US20020123503A1 (en) * 2000-12-21 2002-09-05 Malcolm Ross Cabergoline pharmaceutical compositions and methods of use thereof
US8338442B2 (en) * 2001-03-30 2012-12-25 Toray Industries, Inc. Remedies for psychoneurosis
WO2002092060A1 (en) 2001-05-11 2002-11-21 Endo Pharmaceuticals, Inc. Abuse-resistant controlled-release opioid dosage form
US20030134844A1 (en) * 2001-10-31 2003-07-17 Pfizer Inc. Nicontinic acetylcholine receptor antagonists in the treatment of restless legs syndrome
US20030176822A1 (en) * 2002-03-12 2003-09-18 Morgenlander Joel C. Method of treating restless leg syndrome
BRPI0309544B8 (pt) 2002-04-05 2021-05-25 Euro Celtique Sa preparação farmacêutica oral estável ao armazenamento compreendendo oxicodona e naloxona
US20040048779A1 (en) * 2002-05-06 2004-03-11 Erwin Schollmayer Use of rotigotine for treating the restless leg syndrome
ATE400275T1 (de) 2002-08-30 2008-07-15 Kyowa Hakko Kogyo Kk Adenosin-a2a-rezeptorantagonisten zur behandlung des syndroms der unruhigen beine oder nächtlichen myoklonus
EP1677812A4 (en) 2003-09-17 2010-03-24 Xenoport Inc TREATMENT OR PREVENTION OF NON-REST LEG SYNDROME USING GABA ANALOGUE-BASED PRODRUGS
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) * 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
KR20060030175A (ko) * 2004-10-05 2006-04-10 경북대학교 산학협력단 무정위성 운동 치료용 약학조성물
AP2274A (en) * 2005-01-28 2011-08-19 Euro Celtiques Sa Alcohol resistant dosage forms.
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
US7723345B2 (en) * 2005-12-29 2010-05-25 Lexicon Pharmaceuticals, Inc. Multicyclic amino acid derivatives and methods of their use
US8946300B2 (en) * 2006-04-03 2015-02-03 Teva Pharmaceutical Industries, Ltd. Use of rasagilline for the treatment of restless legs syndrome
WO2008046149A1 (en) * 2006-10-17 2008-04-24 Biologic Health Solutions Pty Ltd Herbal compositions for the prevention or treatment of restless leg syndrome
EP1952813A1 (en) * 2007-02-01 2008-08-06 Ferring International Center S.A. Medicament for the treatment of endometriosis
EP1987815A1 (en) * 2007-05-04 2008-11-05 Schwarz Pharma Ag Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders
US7939665B2 (en) 2007-05-04 2011-05-10 Apotex Pharmachem Inc. Efficient process for the preparation of cabergoline and its intermediates
EP2083008A1 (en) * 2007-12-07 2009-07-29 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
HUE042105T2 (hu) 2009-03-10 2019-06-28 Euro Celtique Sa Oxikodont és naloxont tartalmazó azonnali hatóanyagleadású orális gyógyászati készítmények
RU2011144145A (ru) 2009-04-01 2013-05-10 Биал-Портела Энд Ка, С.А. Фармацевтические препараты, содержащие производные нитрокатехина, и способы их получения
US8690933B2 (en) * 2009-08-31 2014-04-08 Brigham Young University System and method for treating symptoms of restless legs syndrome
US20140045900A1 (en) 2011-02-11 2014-02-13 Bial-Portela & Ca, S.A. Administration regime for nitrocatechols
CA2918004C (en) 2013-07-23 2018-11-20 Euro-Celtique S.A. A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
PL232974B1 (pl) * 2015-12-09 2019-08-30 Ofta Spolka Z Ograniczona Odpowiedzialnoscia Zastosowanie agonistów receptorów dopaminergicznych typu 2 w leczeniu schorzeń oczu wywołanych przez podwyższony poziom śródbłonkopochodnego czynnika wzrostu naczyń
WO2021067751A1 (en) 2019-10-03 2021-04-08 Noctrix Health, Inc. Peripheral nerve stimulation for restless legs syndrome
JP7159169B2 (ja) 2017-01-05 2022-10-24 ノクトリックス ヘルス インコーポレイテッド レストレスレッグス症候群または過活動神経治療

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4526892A (en) * 1981-03-03 1985-07-02 Farmitalia Carlo Erba, S.P.A. Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
US5496836A (en) * 1994-05-05 1996-03-05 Mount Sinai School Of Medicine Of The City University Of New York Use of famotidine and related compounds in the treatment of movement disorders

Also Published As

Publication number Publication date
SK13312000A3 (sk) 2001-05-10
NO20004799L (no) 2000-10-11
PL343593A1 (en) 2001-08-27
ATE313326T1 (de) 2006-01-15
EA002554B1 (ru) 2002-06-27
AU747751B2 (en) 2002-05-23
CA2320204A1 (en) 1999-09-30
WO1999048484A3 (en) 1999-11-25
IL138522A0 (en) 2001-10-31
HUP0101954A2 (hu) 2001-12-28
EA200000994A1 (ru) 2001-02-26
EP1066038B1 (en) 2005-12-21
CZ297284B6 (cs) 2006-10-11
NZ507176A (en) 2003-09-26
EP1066038A2 (en) 2001-01-10
KR20010052222A (ko) 2001-06-25
AU3353199A (en) 1999-10-18
DE69929041T2 (de) 2006-07-20
WO1999048484A2 (en) 1999-09-30
KR100597517B1 (ko) 2006-07-10
DK1066038T3 (da) 2006-04-24
NO20004799D0 (no) 2000-09-26
CN1303286A (zh) 2001-07-11
BR9908953A (pt) 2000-12-05
HUP0101954A3 (en) 2002-09-30
ZA200004452B (en) 2002-02-27
JP2002507562A (ja) 2002-03-12
CZ20003419A3 (cs) 2002-01-16
DE69929041D1 (de) 2006-01-26
ES2255255T3 (es) 2006-06-16
US6114326A (en) 2000-09-05

Similar Documents

Publication Publication Date Title
TR200002759T2 (tr) Bacak uyuşması sendromunun tedavisinde kabergolin kullanımı.
TR200102711T2 (tr) Kriz halindeki başağrılarının iyileştirilmesinde kullanıma yönelik antikonvülsan türevler
DE60123276D1 (de) Piperazinderivate zur behandlung bakterieller infektionen
TR200101481T2 (tr) Doğal bitkisel zaruri yağlar kullanan kanser tedavi kompozisyonu ve yöntemi.
BR0107691A (pt) Sapogeninas substituìdas e seu uso
JO2356B1 (en) N-by-phenyl derivatives (methyl substituted) amino cycloalkan carboxamide
TR200502508T2 (tr) IL-18 İnhibitörlerinin kullanımı.
EP1476419A4 (en) N-BIPHENYLMETHYL AMINOCYCLOALCANECARBOXAMIDE DERIVATIVES
BR9807523A (pt) Quinoxalinas em combinação tripla com inibidores da protease e inibidores de transcriptase reversa como medicamentos para o tratamento de aids.
NO20040726L (no) Kombinasjonspreparater av arylsubstituerte propanolaminderivater med andre aktive forbindelser og anvendelse derav.
NO964238L (no) Halofantrin-fri-base for behandling av malaria og blandinger
TR199900505T2 (tr)
NO20010464D0 (no) Fremgangsmåter og sammensetninger for behandling av gastroösofrageal-reflukssyndrom
CY1108053T1 (el) Ενωση της κυαμεμαζινης και ενος ατυπου νευροληπτικου
HK1024408A1 (en) Use of pramipexole in the treatment of restless legs syndrome
NO20032597L (no) Anvendelse av SARP-1 for behandlingen og/eller forebyggingen av skleroderma
TR200002939T2 (tr) Paroksetin maleat
TR200000005T2 (tr) Sıtmaya karşı ß-alkoksiakrilatlar.
DK1189615T3 (da) Endoparasiticid synergistisk kombination indeholdende cykliske depsipeptider og piperaziner
DK1052991T3 (da) Topisk anvendelse af loperamid til behandling af mikrobielle infektioner
FI961339A0 (fi) Triaryylieteenijohdannaiset käytettäväksi hoidossa
ATE361757T1 (de) Stabile fumagillin-formulierung
BR0009289A (pt) Uso de inibidores da vasopeptidase para tratar angina pectoris
MD980129A (en) Antiherpetic remedy
ES2171080T3 (es) Composicion para la mejora de la fertilidad y su aplicacion.